Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc is well-positioned for growth with a focus on developing innovative therapies for significant unmet medical needs in oncology and COVID-19 treatment. The company’s current valuation is deemed attractive, with updated net present value (NPV) analyses indicating considerable upside potential for its stock price. Achieving key clinical milestones and data is anticipated to serve as strong catalysts, strengthening the overall positive outlook for the company's financial future.

Bears say

Atossa Therapeutics Inc. reported a net loss of $8.7 million, equating to an earnings per share (EPS) of $(0.07), which matched previous estimates but raises concerns over consistent financial performance, given prior losses of $8.4 million at the same EPS level. The company faces numerous significant risks that could impede its financial recovery and growth, including potential failures in clinical trials, regulatory approval process hurdles, and challenges in commercialization and market competition. Additionally, the reliance on successful product development amidst fluctuating investor sentiment and macroeconomic conditions further compounds the overall negative outlook on the stock.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.